Selegiline in Treatment of Cocaine Dependence - 2

This study has been completed.

First Received on September 20, 1999. Last Updated on August 16, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	University of Pennsylvania
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000188

Purpose

The purpose of this study is to assess selegiline as a pharmacotherapy for cocaine dependence.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Selegiline	Phase II

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Selegiline in Treatment of Cocaine Dependence

Resource links provided by NLM:

Drug Information available for: Cocaine hydrochloride Selegiline Selegiline hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Retention
Cocaine use
Cocaine craving

Estimated Enrollment:	0
Study Start Date:	September 1994

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000188

Locations

United States, Pennsylvania
PDVAMC Treatment Research Center
Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Pennsylvania

Investigators

Principal Investigator:

James Cornish, M.D.

University of Pennsylvania

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00000188 History of Changes
Other Study ID Numbers:	NIDA-00144-2, K20-00144-2
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Selegiline
Monoamine Oxidase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Central Nervous System Agents
Therapeutic Uses
Antiparkinson Agents
Anti-Dyskinesia Agents

ClinicalTrials.gov processed this record on February 12, 2012